Thomson Medical 5.5% 5NC1 Senior Unsecured SGD

Shawn Sng  |   24 May 2023  |    245 views

Thomson Medical Group recently announced the issuance of its 5NC1 senior unsecured bonds at a final price guidance of 5.5%. These bonds carry a tenor of 5 years with an attached one-time callable option by the issuer at the end of year 1 (31 May 2024). Upon call redemption, the bonds will be redeemed in full at par + half coupon (2.75%). These bonds are ranked Senior, and in terms of debt repayment they will be paid out before those of its junior debts. The coupon payments for these bonds are paid out semi-annually and are scheduled on 31 May and 30 November each year, with the first coupon payment being paid out on 30 November 2023. This bond is non-rated and the proceeds from this issuance will be deployed for general corporate purposes, refinancing of borrowings, potential acquisition, strategic expansions, general working capital, capex expenditure, and other investments of the Group.


Company Overview

Thomson Medical Group is one of the largest healthcare services providers in the South-East Asia region with operations in both Singapore and Malaysia. The group consists of 3 businesses namely: Thomson Medical Centre – TMC (100% ownership), TMC Life Sciences Berhad (approx. 70% ownership), and Vantagebay Healthcare City (100% ownership). Thomson Medical Group is listed on the main board of the Singapore Exchange (SGX: A50) with a market capital of $1.639 billion as at 24th May 2023. Thomson Medical Group is non-rated.


Thomson Medical Pte Ltd

One of Singapore’s largest private providers of healthcare services for women and children


TMC Life Sciences Berhad

A multi-disciplinary healthcare company listed on the Main Market of Bursa Malaysia Securities Berhad since 2005


Vantagebay Healthcare City

Currently still in its planning stage but is to become a unique and purpose-built integrated hub for healthcare, education, and wellness in Johor Bahru’s City Centre


1H2023 Financials

In 1H2023, the Group’s revenue was recorded at $184 million as compared to the previous 1H2022 which was $145.3 million a 26% increase Y.o.Y. Revenue from the Specialized Services segment grew the most at 41% followed by Hospital Services at 14.6% respectively. The growth in revenue was mainly driven by the increase in patient volume and an increase in average bill size due to higher-intensity cases. The Group’s public-private partnerships such as managing vaccination centres and Transitional Care Facilities had also played a part in Singapore’s revenue contribution. In conjunction, EBITDA has also followed suit and increased by 40.6% Y.o.Y from $39.4 million to $55.4 million during 1H2023. In terms of the geographical breakdown of its revenue, Singapore is still the main contributor at 75.6% while the remaining 24.4% comes from Malaysia. Despite that, Malaysia’s revenue has also seen an improvement with it rising by 23% which was attributable to the phased opening of the new wing at Thomson Hospital Kota Damansara (THKD) from 3Q2022. However, the increase in revenue was offset by an increase in manpower cost due to an increase in headcount, higher utility costs and development of the new wing at THKD. These costs have increased by 26.7% and 10.7% YoY respectively. Additionally, the expansion of TKHD which includes a brand-new Cancer & Theranostics Centre, Nuclear Medicine Centre, Eye Health Centre, Preventive Health and Family Medical Centre, and an increase in bed count from 205 to 535 beds will enable it to meet future healthcare demands.


The Group recorded a net decrease in cash and cash equivalent during 1H2023 of $5.9 million. This decrease was due to the purchases of property and equipment, payments of loans interest, leases liabilities, and dividend payments to shareholders of the company. But this decrease was partially offset by the increase in net cash flow from its operations of $52.8 million. Despite the net decrease in cash and cash equivalent, the Group’s cash and short-term deposits stood at $153.4 million which is sufficient to meet its short-term liabilities of $120.5 million. In terms of the Group’s net gearing ratio, it is currently at 0.8 times and it is expected to increase post-issuance according to its management. The company noted that it will make continuous efforts to reduce net gearing moving forward.


The 1-year callable structure which provides an additional half a coupon upon redemption on this particular bond, the yield to call for these bonds would be approx. 8.18% based on Bloomberg. This is a spread of 465bps as compared to the Singapore 1-year Treasury bill which is hovering around the 3.6% range.


For investors who are looking to lock in at 5.5% for a 5-year period with a possibility of early redemption at a premium call price of 102.75, this new issuance would be an attractive mix to be included within a portfolio.


As the initial offering has closed for subscription, investors who are interested in these notes will have to head onto the bond’s secondary market on our POEMS platform to get hold of them. These notes can be transacted in a minimum lot size of SGD$250K.



Bond Overview

Related Articles

Groupe BPCE 5% 10NC5 Tier 2 SGD

Groupe BPCE recently announced the issuance of its 10NC5 Tier 2 notes at a final price guidance of 5%.

Shawn Sng  |   27 Feb 2024

HSBC – Growth supported by higher rates

In FY202, HSBC growth was supported by higher rates and has reported a growth in its revenue of 30% YoY

Shawn Sng  |   23 Feb 2024

UBS Group 5.75% NC5.5 AT1 SGD

UBS Group recently announced the issuance of its NC5.5 Additional Tier 1 perpetual notes at 5.75%.

Shawn Sng  |   16 Feb 2024


These commentaries are intended for general circulation. It does not have regard to the specific investment objectives, financial situation and particular needs of any person who may receive this document. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. Investors may wish to seek advice from a financial adviser before investing. In the event that investors choose not to seek advice from a financial adviser, they should consider whether the investment is suitable for them.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066